Skip to main content
    Q

    Quince Therapeutics, Inc. (QNCX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $31.73
    +0.00 (+0.00%)

    Market Cap: $32.27M

    Last updated: Oct 13, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(10/26)
    Avg Surprise
    -51.76%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.20
    Range$-1.40 - $-0.83
    3 analysts
    EPS Revisions
    1
    0
    7d
    No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-8.80+86.4%
    60d ago$-1.40+14.5%
    30d ago$-1.10-9.1%
    7d ago$-1.200.0%
    Current$-1.20
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$12.23
    Range$7.89 - $14.93
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$12.23---
    Sep 26EST
    		-$-1.20---
    Jun 26
    Reported Aug 14
    		$-12.31N/A+62.99%Beat+81.1%
    Mar 26
    Reported Apr 10
    		$-152.00$-45.00-237.78%Miss-44605.9%
    Dec 25
    Reported Mar 3
    		$-0.41$-0.18-123.35%Miss+99.3%
    Sep 25
    Reported Nov 12
    		$-50.00$-44.50-12.36%Miss-92.3%
    Jun 25
    Reported Aug 11
    		$-65.02$-46.50-39.83%Miss-10005.7%
    Mar 25
    Reported May 13
    		$-0.34$-0.23-47.83%Miss-56.6%
    Dec 24
    Reported Mar 24
    		$-56.00$-20.00-180.00%Miss-25354.5%
    Sep 24
    Reported Nov 13
    		$-26.00$-20.00-30.00%Miss-17432.0%
    Jun 24
    Reported Aug 13
    		$-0.64$0.00N/ABeat-373.1%
    Mar 24
    Reported May 13
    		$-0.22$0.00N/ABeat+36.5%
    Dec 23
    Reported Mar 10
    		$-0.22$-0.28+21.43%Beat-46.7%
    Sep 23
    Reported Nov 14
    		$-0.15N/AN/ABeat+99.7%
    Jun 23
    Reported Aug 3
    		$-0.14$0.00N/AMiss+99.9%
    Mar 23
    Reported May 15
    		$-0.34$-0.31-10.54%Miss+99.8%
    Dec 22
    Reported Mar 15
    		$-0.15$-0.29+47.84%Beat+80.8%
    Sep 22
    Reported Nov 9
    		$-44.00$-56.72+22.43%Beat+69.9%
    Jun 22
    Reported Aug 9
    		$-102.00$-56.05-81.98%Miss+31.1%
    Mar 22
    Reported May 10
    		$-144.00$-111.91-28.67%Miss+7.7%
    Dec 21
    Reported Mar 1
    		$-0.78$-0.65-20.00%Miss-13.0%
    Sep 21
    Reported Nov 11
    		$-146.00$-148.80+1.88%Beat+0.0%
    Jun 21
    Reported Aug 9
    		$-148.00$-151.65+2.41%Beat-23.3%
    Mar 21
    Reported May 6
    		$-156.00$-138.54-12.60%Miss-27.9%
    Dec 20
    Reported Mar 1
    		$-0.69$-0.73+5.48%Beat-97.1%
    Sep 20
    Reported Nov 12
    		$-146.00$-121.67-20.00%Miss-97.3%
    Jun 20
    Reported Aug 14
    		$-120.00$-121.63+1.34%Beat-5.3%
    Mar 20
    Reported May 12
    		$-122.00$-88.93-37.19%Miss-7477.6%
    Dec 19
    Reported Mar 16
    		$-0.35$-0.40+12.50%Beat-
    Sep 19
    Reported Nov 12
    		$-74.00$-74.35+0.47%Beat-
    Jun 19
    Reported Aug 9
    		$-114.00$-80.00-42.50%Miss-
    Mar 19
    Reported May 9
    		$-1.61$-0.23-600.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.15EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-153.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio14.52xQuick Ratio14.52x
    Trading Statistics
    Beta1.33Avg Volume31.09K
    52-Week High$910.0052-Week Low$15.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$29.71
    SMA 20$29.72
    SMA 50$30.71
    SMA 200$91.78
    EMA 10$30.17
    EMA 20$29.96
    EMA 50$29.41
    EMA 200$94.46

    MACD

    Line: 0.22Signal: 0.00Hist: 0.22

    ADX

    ADX: 21.4+DI: 32.9-DI: 17.8

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down24.0
    PSAR$26.87

    Bollinger Bands

    Upper Band$33.21
    Lower Band$26.23
    %B Position2350%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    56.9

    Momentum Oscillators

    Stoch %K50.0
    Stoch %D43.7
    Williams %R-50.0
    ROC (10d)1.8%
    Momentum0.56
    CCI (20d)95.6
    MFI (14d)55.9

    Volatility Measures

    ATR (14d)$2.43(7.7%)
    StdDev (20d)1.75
    Hist Vol80.2%(High)

    Volume Flow

    VWAP$31.73
    OBV3.6B
    AD Line6665.4B
    CMF (20d)-0.211

    Volume Metrics

    Avg Vol (20d)28.6K
    Vol RatioN/A
    VWMA (20d)$29.75

    Pivot Points

    R3$31.73
    R2$31.73
    R1$31.73
    Pivot Point$31.73
    S1$31.73
    S2$31.73
    S3$31.73

    Advanced Oscillators

    TSI2.62
    Ultimate Osc39.2
    KST-36.22

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$168,000$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$16,000$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0$-16,000$0$0$0N/A$0
    Operating Expenses$79.78M$14.59M$19.35M$13.43M$10.43M$14.86M$12.01M$5.86M$28.19M$11.22M$9.99M$6.09M
    R&D$64.46M$6.84M$12.60M$8.08M$6.55M$8.14M$5.83M$4.92M$4.15M$3.70M$3.43M$1.43M
    SG&A$16.63M$4.27M$3.63M$3.28M$3.34M$4.79M$4.28M$3.63M$4.70M$4.97M$4.97M$4.66M
    Operating Income$-79,782,000$-14,590,000$-19,353,000$-13,430,000$-10,427,000$-14,858,000$-12,012,000$-5,863,000$-28,192,000$-11,218,000$-9,986,000$-6,094,000
    Interest Income$584,000$160,000$227,000$300,000$311,000$406,000$536,000$683,000$823,000$887,000$1.01M$959,000
    Interest Expense$0$0$16.96M$58,000$5.55M$125,000$439,000$0$415,000$388,000$338,000$0
    Income Before Tax$-75,413,000$30.57M$-36,312,000$-13,488,000$-15,982,000$-14,983,000$-12,451,000$-5,479,000$-27,693,000$-11,118,000$-8,843,000$-5,351,000
    Income Tax Expense$75,000$-5,339,000$3.15M$-46,000$67,000$47,000$7,000$13,000$36,000$31,000$51,000$0
    Net Income$-75,488,000$35.91M$-39,458,000$-13,442,000$-16,049,000$-15,030,000$-12,458,000$-5,492,000$-27,729,000$-11,149,000$-8,894,000$-5,351,000
    EBITDA$-75,956,000$30.39M$-37,633,000$-13,988,000$-16,493,000$-15,712,000$-14,264,000$-6,668,000$-28,677,000$-12,223,000$-9,921,000$-7,021,000
    EBIT$-75,997,000$30.41M$-37,484,000$-13,788,000$-16,293,000$-15,389,000$-13,790,000$-6,162,000$-28,101,000$-11,617,000$-9,519,000$-6,310,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QNCX

    News

    PERCEPTIVE ADVISORS LLC Acquires 912,853 Shares of Quince Therap

    PERCEPTIVE ADVISORS LLC has acquired 912,853 shares of Quince Therapeutics Inc (QNCX), marking a new position in the clinical-stage biotechnology company. This transaction, valued at $26.81 per share...

    GuruFocus•10/15/26•Somewhat-Bullish

    Preferred shares underpin a passive stake above 5% in Quince Therapeutics (QNCX).

    James B. Tananbaum reported a 6.0% beneficial ownership stake in Quince Therapeutics (QNCX) through two fund positions in Series C Preferred Stock...

    Stock Titan•10/14/26•Neutral

    Warrants for 456,427 shares are excluded from a reported stake in Quince Therapeutics (QNCX).

    Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported an 8.4% beneficial ownership in Quince Therapeutics (QNCX)...

    Stock Titan•10/14/26•Neutral

    Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72

    Quince Therapeutics has relaunched as IRulya Therapeutics, focusing on LAM-001 for pulmonary diseases, and Raymond James has initiated coverage with an Outperform rating and a USD 72 price target. The company had USD 116...

    ad-hoc-news.de•10/13/26•Bullish

    Quince Relaunches as IRulya Therapeutics with New Leadership

    Quince Therapeutics has relaunched as IRulya Therapeutics, undergoing a legal name change, Nasdaq listing transfer...

    The Globe and Mail•10/10/26•Somewhat-Bullish

    QNCX Valuation and Fair Value

    P/E
    -0.1x
    P/B
    -5.5x
    See GNG's fair value

    QNCX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -153.8%

    QNCX Competitors

    CompanyTicker
    China Pharma Holdings IncCPHI
    Briacell Therapeutics CorpBCTX
    Elutia Inc.ELUT
    Rockwell Medical IncRMTI
    NanoViricides IncNNVC
    CEL-SCI CorpCVM
    CryoCell International IncCCEL
    Milestone ScientificMLSS

    Sector: Healthcare

    QNCX Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    6
    Hold
    1
    Sell
    0
    Strong Sell
    0

    QNCX Bull Case vs Bear Case

    Bull case

    • 87.5% of QNCX's analyst ratings are Buy or Strong Buy.

    Bear case

    • QNCX beat EPS estimates in 12.5% of its last 8 reported quarters.

    QNCX Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -76.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About QNCX

    Does QNCX pay dividends?

    Quince Therapeutics, Inc. (QNCX) does not currently pay a regular dividend.

    What is QNCX's market cap?

    Quince Therapeutics, Inc. (QNCX) has a market capitalization of $32.27M with a current stock price of $31.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with Q

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In